San Ramon, CA, United States of America

Chris Elkin

This inventor holds 1 USPTO granted patent, plus 1 CIPO patent and 1 EPO patent. Top assignee: University of California. Active years: 2006.


% Patents Active = 100.0


 

Average Co-Inventor Count = 3.0

ph-index = 1

Forward Citations = 544(Granted Patents)


Company Filing History:


Years Active: 2006

Loading Chart...
Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: Chris Elkin: Innovator in Nucleic Acid Amplification

Introduction

Chris Elkin is a notable inventor based in San Ramon, CA (US). He has made significant contributions to the field of nucleic acid amplification, particularly through his innovative patent. His work has implications for various applications in biotechnology and molecular biology.

Latest Patents

Chris Elkin holds a patent for a system that enhances chemical amplification based on fluid partitioning. This invention involves partitioning a sample into distinct sections and performing PCR (Polymerase Chain Reaction) on these sections. Another embodiment of his invention includes a system for nucleic acid amplification and detection, which also utilizes partitioning and PCR, followed by the detection and analysis of the partitioned sections.

Career Highlights

Throughout his career, Chris has worked with prestigious organizations, including the University of California and F. Hoffmann-La Roche AG. His experience in these institutions has allowed him to develop and refine his innovative ideas in the field of molecular biology.

Collaborations

Chris has collaborated with several professionals in his field, including Billy Wayne Colston, Jr. and Brian L. Anderson. These collaborations have contributed to the advancement of his research and the successful development of his patent.

Conclusion

Chris Elkin is a distinguished inventor whose work in nucleic acid amplification has the potential to impact various scientific fields. His innovative approach to partitioning samples for PCR demonstrates his commitment to advancing biotechnology.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…